(1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.
(1S,2E,4S,6R,7E,11E)-2,7,11-Cembratriene-4,6-diol (1) and its 4-epi-analog (2) are the cembranoid precursors to several key flavor ingredients in most Nicotiana (tobacco) species. Nearly 40-60% of 1 and 2 are purposely degraded during the commercial tobacco fermentation. However, 1 and 2 display promising bioactivities, including anticancer. Breast cancer is the most diagnosed cancer in women and ranked second female disease killer. The receptor tyrosine kinase c-Met correlates with aggressiveness of certain breast cancer phenotypes and thus considered a valid therapeutic target. This study reports the discovery and optimization of the tobacco-based cembranoid 1 as a novel c-Met inhibitory scaffold using combined structure- and ligand-based approaches. 1 displayed antiproliferative, anti-migratory and anti-invasive effects against the c-Met overexpressing MDA-MB-231 breast cancer cells at moderate μM concentrations. The Z'-LYTE kinase platform and Western blot analysis identified c-Met as a potential macromolecular target. Rationally designed carbamate analogs were proposed to probe additional targeted c-Met interactions and improve the cellular potency. The 6-phenyl carbamate 3 showed enhanced c-Met inhibitory activity. Structure-activity relationships of different substituents on the 3's phenyl moiety were studied. The most active analog 20 showed potent in vitro anticancer activity against the MDA-MB-231 breast cancer cells at low μM concentrations, with minimal toxicity on the non-tumorigenic MCF-10A mammary epithelial cells. Cembranoid 20 potently inhibited the c-Met catalytic activity in Z'-LYTE kinase assay and various cellular c-Met-driven signaling pathways. Furthermore, 20 displayed a robust antitumor activity in a breast cancer xenograft athymic mouse model and thus promoted to the lead rank. Cembranoids are novel c-Met inhibitors appropriate for future use to control c-Met dependent malignancies.
Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Hassan Y
HY
Ebrahim
Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Mohamed M
MM
Mohyeldin
Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Mohammad M
MM
Hailat
Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA. Electronic address: elsayed@ulm.edu.
Khalid A
KA
El Sayed
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004224:Diterpenes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D062105:Molecular Docking Simulation; D015394:Molecular Structure; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
C569865:(1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol; D000970:Antineoplastic Agents; D004224:Diterpenes; D047428:Protein Kinase Inhibitors; D019859:Proto-Oncogene Proteins c-met
Breast cancer; Hit-to-lead; Rational design; Semisynthesis; Tobacco cembranoids 1; c-Met
Bioorg Med Chem Lett. 2010 Jul 15;20(14):4223-7
20570511
Oncology. 1988;45(2):122-6
3353074
Bioorg Med Chem Lett. 2015 Apr 1;25(7):1597-602
25736998
J Nat Prod. 2008 Jan;71(1):117-22
18177013
Toxicon. 2009 Dec 15;54(8):1174-82
19281835
PLoS One. 2014 May 21;9(5):e97622
24849787
Methods Mol Biol. 2013;979:65-70
23397389
Nat Rev Drug Discov. 2012 Nov;11(11):822
23123931
Cell Cycle. 2011 Jun 15;10(12):1940-7
21555915
Pathobiology. 2011;78(2):99-114
21677473
Cancer. 2003 Apr 15;97(8):1841-8
12673709
Cell. 1994 Apr 22;77(2):261-71
7513258
Mini Rev Med Chem. 2008 Nov;8(13):1312-27
18991750
Int J Cancer. 2005 Feb 10;113(4):678-82
15455388
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19
22128289
Cell Res. 2005 Jan;15(1):49-51
15686627
Int J Oncol. 2001 Oct;19(4):857-63
11562767
Breast Cancer Res. 2000;2(3):154-7
11250704
Curr Med Chem. 2008;15(5):422-32
18288997
J Chem Biol. 2009 Aug;2(3):131-51
19568781
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
26742998
Bioorg Med Chem. 2008 Mar 15;16(6):2886-93
18222089
J Comput Aided Mol Des. 2011 Apr;25(4):349-69
21487786
Cancer Metastasis Rev. 2003 Dec;22(4):309-25
12884908
Phytother Res. 2016 Apr;30(4):557-66
26744260
PLoS One. 2015 Mar 26;10(3):e0121540
25811857
World J Clin Oncol. 2014 May 10;5(2):125-33
24829859
Mutat Res. 2011 Jul-Oct;728(1-2):23-34
21605699
Neurotoxicology. 2014 Sep;44:80-90
24928201
Nat Prod Rep. 1987 Jun;4(3):237-76
3313125